Dear Biotechnology Peers,
On behalf of the BIOHK2021, we would like to cordially invite you to the first international biotech conference in Hong Kong.
Biotechnology has emerged as one of the fastest growing sectors in Hong Kong and China in recent years. Recognizing its potential, the government has offered strong support through investment towards research and development and the building of infrastructure to foster close connections between industry, academia and investors. According to the Research Grants Council, between 2013/14 and 2017/18, 803 biotechnology-related projects in local universities were publicly-funded amounting to HK$1.2 billion, while outside of academia, through the Innovation and Technology Fund, over 460 biotechnology projects have been funded including those related to non-invasive prenatal diagnosis, robotics-assisted minimally invasive surgery and mini artificial heart.
Hong Kong, often considered the gateway to China due to its unique status as a special administrative region, offers a rich source of opportunities for overseas investors looking to capitalize the continued growth of the Greater Bay Area (GBA) – a scheme initiated by the Chinese government to link Hong Kong, Macau and 9 other cities along the Pearl River Estuary and form an international technology and innovation centre rivalling that of Silicon Valley. With its strong exposure and international integration, Hong Kong has become the go-to stepping stone for Chinese companies looking to expand abroad. New listing rules adopted by the Hong Kong Stock Exchange (HKEX) allowed pre-revenue biotech companies to be listed on the exchange. A first in Asia, it ensured more capital could flow freely towards a sector that'd been largely deprived in the region until recently. As of April 30, 2020, of the 16 pre-revenue biotech companies that completed their IPOs since the new listing rule, almost half have experienced a share price increase upwards of 60% from its issuance price. As such, owing to its geopolitical advantage, large number of world class universities and its position as the No. 1 biotech IPO market in Asia, Hong Kong has the potential to be at the epicentre of Asia’s biotech revolution and it is our hope that BIOHK2021 will help set this in motion.
Preparations for BIOHK2021 began in early 2019 and it has since weathered through a social unrest and a global pandemic. Though it has already twice been postponed, we believe it has only made the convention better than ever, with more speakers and supporting organisations from all over the world including Europe and the US. COVID-19 has highlighted the importance of biotechnology. From rapid detection methods to vaccines, new drug developments and treatment equipment, biotechnology is the key to ending this pandemic, and it is our mission to showcase these advancements at BIOHK2021.
As the first of many BIOHK events, the convention represents a new chapter for both the local biotech industry and the city itself, as such we wanted to wait until it was safe to travel, so to meet everyone in person and to celebrate the event together. We believe business opportunities are best made face to face, as such BIOHK2021 will offer one of the first large scale networking opportunities after the pandemic. We will work tirelessly for your support and will do everything in our power to ensure the event is an overwhelming success.
As a city with a rich history in industrial development and innovation, and one that is frequently coined “Asia’s World City”, there is no better place to bring biotech companies from East and West together other than here at BIOHK2021. Take charge and seize the many opportunities available and engage with global industry leaders at BIOHK2021.
We look forward to seeing you in BIOHK2021.
Professor Albert Cheung-hoi YU, PhD, JP
Mr. CHEN Tony
Mr. CHEN Ping